ADAP

Adaptimmune Therapeutics PLC Sponsored ADR · NASDAQ

Sector Health Technology
Industry Biotechnology
Website adaptimmune.com
Employees(FY) 534
ISIN US00653A1079

Performance

-4.21%

-10.36%

-40.11%

-31.26%

-23.72%

YTD

+37.07%

Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Advanced Technical Analysis

Technical Analysis of ADAP 2024-12-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, a neutral Oscillators Score of 50 suggesting indecision, and a Technical Score of 30 reinforcing the bearish outlook. This combination signals caution for potential investors, as the prevailing trend appears to be nega...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ADAP

Stock Rank

Recent News & Updates

2024-12-18 18:30
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK(Newsfilecorp)
2024-12-02 03:00
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)(Newsfilecorp)
2024-11-14 16:00
Halozyme bids for Evotec; BeiGene gets a new name(Yahoo Finance)
2024-11-13 22:55
Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints(Yahoo Finance)
2024-11-13 13:15
Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ...(Yahoo Finance)
2024-11-13 03:05
Adaptimmune Reports Q3 2024 Financial and Business Updates(Newsfilecorp)
2024-11-12 20:00
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial(Newsfilecorp)
2024-11-04 20:19
Adaptimmune to Participate in Scientific and Medical Conferences this November and December(Newsfilecorp)
2024-10-31 05:20
Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024(Newsfilecorp)
2024-09-19 20:35
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing(Globenewswire)
2024-09-16 00:07
Life Sciences Virtual Investor Forum Agenda Announced for September 19th(Globenewswire)
2024-08-27 20:00
Adaptimmune to Participate in Two Bank Conferences this September(Newsfilecorp)
2024-08-11 19:00
Adaptimmune Reports Q2 2024 Financial and Business Updates(Newsfilecorp)
2024-08-08 19:13
Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval(Yahoo Finance)
2024-08-04 20:00
Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024(Newsfilecorp)
2024-08-01 23:53
Adaptimmunes Tecelra gains accelerated approval for synovial sarcoma(Yahoo Finance)
2024-08-01 20:46
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade(Yahoo Finance)
2024-08-01 18:54
First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer(Yahoo Finance)
2024-08-01 08:20
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor(Businesswire)
2024-07-24 11:13
Why Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now?(Yahoo Finance)
2024-07-02 23:11
3 Biotech Moonshots With Imminent Catalyst Potential(Yahoo Finance)
2024-07-02 18:00
5 FDA decisions to watch in the third quarter(Yahoo Finance)
2024-06-03 00:00
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise(Newsfilecorp)
2024-05-30 19:39
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday(Investorplace)
2024-05-30 04:01
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications(Globenewswire)
2024-05-30 04:01
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications(Newsfilecorp)
2024-05-16 18:49
Mizuho Slashes Price Target on Adaptimmune Therapeutics to $3 From $9, Keeps Buy Rating(Yahoo Finance)
2024-05-15 20:18
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2024 Earnings Call Transcript(Insidermonkey)
2024-05-15 00:53
ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024(Investorplace)
2024-05-14 23:07
Adaptimmune Therapeutics Enters Into $125 Million Term Loan Facility With Hercules Capital(Yahoo Finance)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.